Genocea Biosciences Inc expected to post a loss of 20  cents a share - Earnings Preview

Genocea Biosciences

08/03/2022 17:31

* Genocea Biosciences Inc  GNCA.OQ   GNCA.O  is expected
to show
no change in quarterly revenue when it reports  results on March
10. 
    * ​Refinitiv's mean analyst estimate for Genocea Biosciences
Inc
is for a loss of 20 cents per share. For the same quarter last
year, the company reported a loss of 23 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Genocea
Biosciences Inc is $6​, above​ its last closing price of $1.01.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.20       -0.20      -0.05     Beat    74.7
 Jun. 30 2021  -0.18       -0.18      -0.06     Beat    67
 Mar. 31 2021  -0.20       -0.20      -0.17     Beat    14.1​
 Dec. 31 2020  -0.21       -0.21      -0.23     Missed  -10.6
 ​​Sep.        -0.25       -0.24      -0.08     Beat    66.9
 30 2020                                                
 Jun. 30 2020  -0.41       -0.40      -0.39     Beat    3.7​
 Mar. 31 2020  -0.34       -0.35      -0.46     Missed  -30.7
 Dec. 31 2019  -0.37       -0.39      -0.34     Beat    12.8
 This summary was machine generated March 8 at 17:31 GMT.  All
figures in US dollars  unless otherwise stated